Consumer health companies operating within the European Union are facing an avalanche of regulation, from the revision of the region’s pharmaceutical legislation to the ongoing issues with implementing the new medical devices regulation.
On top of these sector-specific, yet still wide-ranging legislative changes, sits the EU Green Deal. Aiming for “net zero” emissions of greenhouse gases by 2050, the Green Deal is itself a regulatory behemoth consisting of numerous directives, strategies and frameworks.
The European Commission recently announced that it would like to see a 90% net greenhouse gas emissions reduction by 2040 compared to 1990 levels, with a legislative proposal to be made following the European elections later this year.
To help companies navigate this legislative storm, HBW Insight has produced the infographic below, bringing together the main regulations and directives supporting the Green Deal.
Each piece of legislation impacts the European consumer health industry in different ways, and with varying levels of severity.
How direct the impact of each legislative action is or will be on industry is noted in the infographic, along with how much attention companies should be paying at this point in time. The most critical appear first in red, followed by those that are very important in orange, and finally those that are worth considering in yellow.
Given the Green Deal and the parts of this regulatory puzzle are constantly moving and changing shape, the infographic represents a snapshot in time to help consumer health companies plan for the immediate future.
And immediate this future is. The first three items – the EU Pharmaceutical Legislation Revision, Packaging and Packaging Waste Regulation and the Urban Wastewater Treatment Directive – are in trilogue negotiations between the Commission, EU Parliament and Council, which means agreement is likely to be reached soon with publication in the Official Journal of the European Union to follow.
